secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001193125-24-005292
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharmaceuticals closes $150M public offering of 10M shares at $15; net proceeds ~$140.1M
--------------------------------------------------------------------------------

- Sold 10,000,000 shares of common stock at $15.00 per share in an underwritten public offering.
- Net proceeds after underwriting discounts and estimated expenses were approximately $140.1 million.
- Underwriters granted a 30-day option to purchase up to an additional 1,500,000 shares.
- Proceeds to be used for potential acquisition of new product candidates and general corporate purposes.
- Bookrunners: BofA Securities, Citigroup, Piper Sandler, Cantor, Truist Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524005292/0001193125-24-005292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312524005292/d702064d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-005292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer